TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04998981
Drug: K-877 0.1 mg tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: K-877 0.1 mg tablet x 2 twice daily
Study: NCT04998981
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet x 2 twice daily
Study: NCT04998981
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule once daily
Study: NCT04998981
Drug: K-877 0.1 mg tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: K-877 0.1 mg tablet twice daily
Study: NCT04998981
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet twice daily
Study: NCT06510283
Drug: Taitacept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telitacicept will be subcutaneously injected at a dose of 240mg per week, lasting for at least 24 weeks.
Study: NCT06530966
Drug: ICP-332 Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible patients will receive ICP-332 tablets orally as per the protocol
Study: NCT06025084
Drug: Egg Shell nanoparticles
Normalized name: egg shell membrane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evaluate the effects of egg shell nanoparticles combined with Titanium dioxide nanoparticles in the treatment of dentin hypersensitivity at different time intervals.
Study: NCT06530966
Drug: ICP-332 Placebo Tablets
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible patients will receive ICP-332 placebo tablets orally as per the protocol
Study: NCT05973253
Drug: prepared drop of medroxy progestrone acetat 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: In 37 patients who are candidates for photorefractive keratectomy, at the end of the procedure, in one eye randomly, in addition to the antibiotic drop that is routinely placed at the end of the procedure, a drop of prepared medroxyprogesterone is also placed. Then, a bandage contact lens is placed on the eyes, and the patient receives the routine post-procedure drops that include betamethasone and ciprofloxacin drops for both eyes.
Study: NCT06584058
Drug: HPP737
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[14C\]HPP737 oral preparation, 20mg（150μCi）, once
Study: NCT04887285
Drug: Intravenous sedation
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedation will be administered using low-dose midazolam and/ or fentanyl. We will use a wide range of dosing (1-5 mg for midazolam, up to 150 mcg for fentanyl) to maximize generalizability and account for widespread variability in clinical circumstances, medical practice and patient response (personalized medicine). Sedation will be titrated to effect by a board-certified or eligible anesthesiologist so that patients remain responsive to verbal stimuli.
Study: NCT06306274
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ointment
Study: NCT06039163
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants randomized to placebo group in escalation and expansion phase will receive placebo administered via inhalation for 5 consecutive days (Day 1 to Day 5).
Study: NCT05683301
Drug: Perindopril + Indapamide
Normalized name: indapamide / perindopril
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single pill combination of dual antihypertensive agent
Study: NCT05683301
Drug: Amlodipine + Indapamide
Normalized name: Indapamide
DrugBank: Indapamide (DB00808)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single pill combination of dual antihypertensive agent
Study: NCT05877547
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC injection of matching placebo
Study: NCT03934905
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants will be dosed, based on weight, in a double-blind fashion with identical appearing placebo or sulforaphane caplets in a daily dose for 12 weeks of: two caplets for individuals \<100 lb., four caplets for individuals 100-200 lb. and eight caplets for individuals \>200 lb. Avmacol or placebo will be prescribed by Dr. Awasthi and will be dispensed by local pharmacy or study coordinators at TTUHSC/UMC Lubbock. We will be doing pill counts to make sure that volunteers have used as directed. We will measure the Sulforaphane level in plasma by well-established method.
Study: NCT04676802
Drug: NSAID capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1, Ibuprofen 400-mg and 1, Acetaminophen 500-mg capsule per dosage
Study: NCT04676802
Drug: Opioid capsule
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1, Oxycodone 5-mg capsule and 1, placebo capsule per dosage
Study: NCT04939428
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule matched to molnupiravir 200 mg capsules taken by mouth.
Study: NCT05407220
Drug: HCP1904-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: take it once per period
Study: NCT05407220
Drug: HCP1904-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: take it once per period
Study: NCT06233630
Drug: Control Test - spinal anesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: No peripheral nerve block Only spinal anesthesia
Study: NCT06095206
Drug: GenSci094
Approvals — FDA: no, EMA: no, PMDA: no
Description: On the morning of day 1 pre-meal, a single SC injection of 150 μg GenSci094 was administered in the abdominal wall.
Study: NCT06536036
Drug: SIM0270
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use according to the prescribed protocol
Study: NCT04940546
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mode of administration: Orally
Study: NCT06205082
Drug: LIT-00814
Normalized name: ZINC OXIDE 20.8 g in 100 mL TOPICAL SPRAY [Glow Baby Super Lit SPF 30]
Approvals — FDA: no, EMA: no, PMDA: no
Description: LIT-00814 is an oral tablet.
Study: NCT05515796
Drug: CapeOx
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin(130mg/m2) on day 1 of each cycle and Capecitabine:Dose of 1000mg/m2,14days
Study: NCT04833140
Drug: Estradiol patch
Normalized name: Estradiol Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patch will provide 100mcg of estradiol daily.
Study: NCT04833140
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch will contain no estradiol.
Study: NCT06119529
Drug: LY3872386
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered either IV or SC.
Study: NCT06119529
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered either IV or SC.
Study: NCT05922436
Drug: Cleviprex®
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous injection
Study: NCT06094140
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2400mg/m2 by continuous infusion via pump over 46 hours starting on day 1
Study: NCT05741697
Drug: bi-level ventillation
Normalized name: bis-ethoxydiglycol succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: non-invasive mechanical ventilation
Study: NCT05138562
Drug: Placebo Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 x placebo capsules, QD
Study: NCT05138562
Drug: Active Comparator: TU2670 320mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 320mg (80mg x 4), QD
Study: NCT05138562
Drug: Active Comparator: TU2670 240mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240mg (80mg x 3 + placebo x 1), QD
Study: NCT05138562
Drug: Active Comparator: TU2670 120mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120mg (80mg x 1 + 20mg x 2 + placebo x 1), QD
Study: NCT01714089
Drug: RNS60 125 ml
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01714089
Drug: RNS60 250 ml
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05550337
Drug: AKLIEF®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream
Study: NCT05550337
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream
Study: NCT05719961
Drug: INS062 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part I: A single dose of 1.2noml/kg is administered.
Study: NCT06615193
Drug: HDM2005
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDM2005 will be administered via IV infusion.
Study: NCT05719961
Drug: HR20014 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part II: Ascending single doses at three dose levels
Study: NCT06613776
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 empty capsules of amoxicillin 500mg (placebo), one hour before surgery
Study: NCT06697522
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blank comparator
Study: NCT06697327
Drug: (Daunorubicin, Cytarabine, Venetoclax)
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Drugs：Daunorubicin~  * Dosage: 40 mg/(m²·d) on days 1 to 3~ * Other names: Cerubidine, Daunomycin, Rubidomycin~* Drugs：Cytarabine~  * Dosage: 100 mg/(m²·d) on days 1 to 5~ * Other names: Ara-C, Cytosine Arabinoside, Cytosar-U~* Drugs：Venetoclax~  * Dosage: 100 mg on day 1, 200 mg on day 2, and 400 mg from days 3 to 14~ * Other names: ABT-199, Venclexta, Venclyxto
Study: NCT06697327
Drug: (Daunorubicin, Cytarabine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Drugs：Daunorubicin~  * Dosage: 60 mg/(m²·d) on days 1 to 3~ * Other names: Cerubidine, Daunomycin, Rubidomycin~* Drugs：Cytarabine~  * Dosage: 100 mg/(m²·d) on days 1 to 7~ * Other names: Ara-C, Cytosine Arabinoside, Cytosar-U
Study: NCT05844787
Drug: MT101-5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT04291599
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will be randomized to either receive opioid (standard of care) or opioid-sparing analgesia.
Study: NCT04291599
Drug: Opioid
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be randomized to either receive opioid (standard of care) or opioid-sparing analgesia
Study: NCT06299605
Drug: Vonoprazan-Amoxicillin-Tetracycline-Bismuth quadruple regimen for 14 days
Normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Vonoprazan 20mg bid + Amoxicillin 1000mg bid + Tetracycline 500mg qid + Bismuth 220mg bid for 14 days
Study: NCT06299605
Drug: Vonoprazan-Amoxicillin-Tetracycline triple regimen for 14 days
Normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Vonoprazan 20mg bid + Amoxicillin 1000mg bid + Tetracycline 500mg qid for 14 days
Study: NCT06299605
Drug: Vonoprazan-Amoxicillin-Tetracycline triple regimen for 7 days
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Vonoprazan 20mg bid + Amoxicillin 1000mg bid + Tetracycline 500mg qid for 7 days
Study: NCT05590338
Drug: GSK1070806
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive GSK1070806
Study: NCT05590338
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo
Study: NCT05735535
Drug: Antiviral Agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: two-drug one-pill once day
Study: NCT05288543
Drug: IPG7236- Single ascending dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive IPG7236 tablets orally once on Day 1 in a fasted state
Study: NCT06121570
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin will be administered at 60 mg/m\^2 IV on Day 1 of Cycles 1-2 of the neoadjuvant chemotherapy of the study.
Study: NCT06121570
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be administered at 600 mg/m\^2 IV on Day 1 of Cycles 1-2 of the neoadjuvant chemotherapy of the study.
Study: NCT06121570
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be administered at 500 mg/m\^2 IV daily for three days. Cyclophosphamide will be initiated five days prior to the anticipated LNL transfer, and the precise timing will depend on the rate of in vitro LNL growth.
Study: NCT05474846
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by PO
Study: NCT04903002
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive an intranasal placebo containing the same ingredients as the oxytocin nasal spray with the exception of active oxytocin. Administration schedule and procedure will be identical to that described in 24-IU oxytocin.
Study: NCT06517199
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo 1 tab/day for 28 days
Study: NCT06365047
Drug: 1000 ppm F toothpaste
Normalized name: F
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control
Study: NCT00000730
Drug: Leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05117034
Drug: Nacl 0.9%
Normalized name: DEXTROSE 5%/NACL 0.9% INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative intravenous administration of 0.08 ml/kg NaCl 0.9% at dura closure.
Study: NCT04727086
Drug: BP1.3656
Approvals — FDA: no, EMA: no, PMDA: no
Description: BP1.3656 will be administered in tablet form once daily at a dose of 30 µg/day for the first 4 days of the intervention phase, followed by a dose increase to 60 µg/day for the remaining 10 days. If the highest dose is not tolerated, it will be lowered to 30 µg.
Study: NCT04727086
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered once daily in tablet form.
Study: NCT04861298
Drug: standard of care for COVID-19 as per the hospital guidelines
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospital standard of care treatment for COVID-19
Study: NCT05191875
Drug: Saccharomyces Boulardii 250 MG
Normalized name: Saccharomyces boulardii 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saccharomyces Boulardii:~0.25 g \* 6, Produced by The French encyclopedia pharmaceutical Factory
Study: NCT05191875
Drug: Ilaprazole.Doxycycline. Furazolidone. Colloidal Bismuth Tartrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ilaprazole:~5mg\*6, produced by Livzon Pharmaceutical Group Inc~Doxycycline:~0.1 g \* 10, produced by Jiangsu Yongxin Ltd.~Furazolidone:~0.1g\*100 produced by Tianjin Lisheng Pharmaceutical Co., LTD~Colloidal Bismuth Tartrate:~55 mg \* 36,produced by Shanxi Xinbaoyuan Pharmaceutical Co., LTD
Study: NCT05233085
Drug: AZD4041
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive oral solution of AZD4041 as stated in arm description.
Study: NCT06329206
Drug: GH2616 Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH2616 tablets will be given orally
Study: NCT05653323
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension for oral administration.
Study: NCT05690100
Drug: GeliO3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-inflammatory Gel which has a beneficial role on wound healing
Study: NCT05236543
Drug: AZD4831
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive single oral dose only on Day 1 and Day 11.
Study: NCT04949399
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline Injection
Study: NCT06649344
Drug: HRS9531 Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS9531 injected subcutaneously once weekly.
Study: NCT06615440
Drug: Alpha blocker
Normalized name: ALPHA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: prazosin will be given to all children with systemic manifestations (orally or by nasogastric tube) at a dose of 30 μg/kg/dose;first repeat dose at 3 h followed by every 6 h till recovery. All patients will be monitored for clinical improvement with vital signs
Study: NCT06614621
Drug: Maintenance treatment period:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adebrelimab：20mg/kg或1200mg，IV, Q3W； Apatinib Mesylate Tablets：250mg，P.O，qod
Study: NCT05009290
Drug: SHR3680
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group: SHR3680 240 mg orally once daily before or after breakfast, 28 days per cycle for a total of 12 treatment cycles (6 cycles before and 6 cycles following radical prostatectomy).~Goserelin acetate sustained-release depot: 10.8 mg administered subcutaneously into the anterior abdominal wall once every 3 cycles (12 weeks) for a total of 12 cycles.
Study: NCT05009290
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group ：Placebo 240 mg orally once daily before or after breakfast, 28 days per cycle for a total of 12 treatment cycles (6 cycles before and 6 cycles following radical prostatectomy).~Goserelin acetate sustained-release depot: 10.8 mg administered subcutaneously into the anterior abdominal wall once every 3 cycles (12 weeks) for a total of 12 cycles.
Study: NCT06613997
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 21 consecutive days
Study: NCT06617455
Drug: Placebo Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT05712278
Drug: SAR445419
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cell suspension, by intraveneous (IV) injection
Study: NCT05995236
Drug: PSMA radionuclide therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collect clinical data related to treatment of PSMA-positive metastatic castration-resistant prostate cancer treated with PSMA radionuclide therapy
Study: NCT05152576
Drug: OnabotulinumtoxinA X
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular Injection
Study: NCT05152576
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular Injection
Study: NCT06258408
Drug: BB102 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: BB102 tablets will be administered orally once daily(QD).
Study: NCT06696482
Drug: Placebo 10 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 10 mg, encapsulated in an opaque capsule to facilitate blinding of participant and researcher
Study: NCT06711289
Drug: Spinal anesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following the standard of care, the patients received spinal anesthesia. The type and dosage of the local anesthetic were at the discretion of the treating anesthesiologist.
Study: NCT05343455
Drug: DFD-29
Approvals — FDA: no, EMA: no, PMDA: no
Description: DFD-29 (40 mg) extended release capsules
Study: NCT05343455
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline 40 mg capsules
Study: NCT06144684
Drug: GUB014295
Approvals — FDA: no, EMA: no, PMDA: no
Description: GUB014295 is a long-acting amylin analogue in development, a single subcutaneous dose is administered in part 1, multiple doses administered in part 2 of the study
Study: NCT01104844
Drug: Full Dose Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen + ibuprofen, 2 tablets every 6 hours, with food for 24 hours (i.e a total of 4 x 1000/300 mg doses of study drug comprising of 8 tablets)
Study: NCT01104844
Drug: Quarter dose strength
Normalized name: Quarter Mate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational drug quarter dose strength (acetaminophen 125mg + ibuprofen 37.5mg) i.e. 2 tablets equating to 1/4 the dose in the standard investigational drug.
Study: NCT01104844
Drug: Half dose strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational drug half dose strength (acetaminophen 250mg + ibuprofen 75mg) i.e. 2 tablets equating to 1/2 the dose in the standard investigational drug
Study: NCT01104844
Drug: Acetaminophen standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen standard dose 500mg i.e. 2 tablets equating to the same acetaminophen dose as in the standard investigational drug
Study: NCT01104844
Drug: Ibuprofen low dose
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen low dose 150mg tablet i.e. 2 tablets equating to the same ibuprofen dose as in the standard investigational product
Study: NCT01104844
Drug: Ibuprofen high dose
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen high dose 300mg i.e. 2 tablet equating to twice the ibuprofen dose as in the standard investigational drug
Study: NCT01104844
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 placebo tablets
Study: NCT05165069
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo 0.5mg / time, 3 times / day,was taken continuously for 6 months
Study: NCT05293158
Drug: Hepatect CP 50 I.E./ml infusion solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of i.v. (intravenously) HBIGs for ≥6-weeks:~Day (D) 0-7: 10.000 IU D14 until end-of-treatment: 10.000 IU once per week HBIGs will be given until LT/liver resection.
Study: NCT05784155
Drug: Test Drug(JW0302) or Reference Drug(C2206)
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test Drug: single administration of JW0302 Reference Drug: single administration of C2206~Tablet, Oral, QD for 1 Days, Washout period is more than 14 days after administration
Study: NCT06426654
Drug: sintiliman plus LDRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will start with one cycle of neoadjuvant therapy of sintilimab: sintilimab 200 mg, iv drip, d1, q3w.~LDRT will be performed in the target area. After radiotherapy, patients will receive another three cycles of sintilimab.~Radical D2 gastric cancer resection will be performed 4-6 weeks after the last administration of sintilimab.~The adjuvant therapy will start in 4-6 weeks after the surgery, and we recommend adjuvant treatment with sintilimab for up to 10 cycles.
Study: NCT06342258
Drug: Ultradent Ultra Seal XT Plus
Normalized name: Flexall Ultra Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each child who has erupted, bilateral permanent molars that qualify for the study and agree to participate will have a side (right or left side) of their mouth randomized for bond that will be cured prior to sealant placement. Daily flossing and oral hygiene instructions will be taught to patients of all study groups. Sealant will be placed using a dental suction isolation system, such as DryShield isolation after prophy cup polish with pumice. No enameloplasty will be conducted.
Study: NCT05051163
Drug: Gentamicin
Normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7 days of once daily dosing
Study: NCT05686564
Drug: ALXN1840
Approvals — FDA: no, EMA: no, PMDA: no
Description: bis-choline tetrathiomolybdate